The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
|Videos|March 15, 2011
Dr. Jabbour on Second-Generation TKIs in CML
Author(s)Elias Jabbour, MD
Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.
Advertisement
Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation tyrosine-kinase inhibitors (TKIs) for patients with chronic myelogenous leukemia (CML), a cancer that starts inside bone marrow.
Taken at the 2010 ASCO Annual Meeting.
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
FDA Approves Pimicotinib for Symptomatic TGCT
4
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
5